Bassin Parisien; Centre; Indre-et-Loire
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.20 - Manufacture Of Pharmaceutical Preparations

225 jobs
Number of planned job losses
Job loss
Announcement Date
28 November 2023
Employment effect (start)
1 January 2024
Foreseen end date
31 December 2025


The management of Recipharm has announced that it will cease operations at its Monts site during 2025. The gradual decline in production had already led the company to announce a voluntary redundancy plan for 95 employees in April 2023 FR-Recipharm-2023a. Management has announced its priority to actively seek a buyer for the site. The site had benefited from investment to produce the Moderna vaccine at the time of Covid-19, but currently it is suffering from profitability problems. The group benefited from state aid of €35 million out of a total investment of €50 million. According to Henri Alfandari, the Horizons MP for Indre-et-Loire, as cited by France Bleu Touraine, the group, which only received €15 million, is obligated to reimburse the funds. Given this prospect, an effect on employment is already expected, with natural departures that will not be replaced. The majority of job losses will occur in 2025.



Eurofound (2023), Recipharm Monts, Closure in France, factsheet number 200657, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/200657.